Breaking News, Collaborations & Alliances

Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine

Will produce mRNA at its Canadian facility in Mississauga, Ontario.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

National Resilience, Inc., has signed a deal with Moderna to manufacture drug substance for the Moderna COVID-19 vaccine.   Under the terms of the multi-year agreement, Resilience will produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario in Canada, for distribution worldwide.   “Moderna’s COVID-19 vaccine has saved countless lives, and we’re excited to manufacture mRNA for this important vaccine,” said Rahul Singhvi, Sc.D, CEO, Resilience. “This collaboration has...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters